• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.

作者信息

De Sanctis R, Bruzzi P, Zambelli A

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan.

Department of Health Sciences, University of Genoa, Genova, Italy.

出版信息

Ann Oncol. 2024 Dec;35(12):1201-1202. doi: 10.1016/j.annonc.2024.08.2345. Epub 2024 Sep 3.

DOI:10.1016/j.annonc.2024.08.2345
PMID:39236982
Abstract
摘要

相似文献

1
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3' by M. P. Goetz et al.揭开肿瘤学疗效终点的方法学见解：从统计学到临床，反之亦然。致编辑的信，关于M. P. 戈茨等人的“阿贝西利联合非甾体芳香化酶抑制剂作为HR +、HER2 - 晚期乳腺癌的初始治疗：MONARCH 3的最终总生存结果”
Ann Oncol. 2024 Dec;35(12):1201-1202. doi: 10.1016/j.annonc.2024.08.2345. Epub 2024 Sep 3.
2
Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):747-748. doi: 10.1016/j.annonc.2024.05.543. Epub 2024 Jun 3.
3
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3.
4
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.阿贝西利联合非甾体芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌的初始治疗：MONARCH 3 的最终总生存结果。
Ann Oncol. 2024 Aug;35(8):718-727. doi: 10.1016/j.annonc.2024.04.013. Epub 2024 May 8.
5
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.MONARCH 3 研究：阿贝西利联合芳香化酶抑制剂作为 HR+/HER2-晚期乳腺癌初始内分泌治疗的疗效和安全性
Oncologist. 2020 Sep;25(9):e1346-e1354. doi: 10.1634/theoncologist.2020-0084. Epub 2020 Jun 24.
6
Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.阿贝西利联合非甾体芳香化酶抑制剂或氟维司群用于激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌女性患者：随机III期MONARCH plus试验的最终结果
Chin Med J (Engl). 2024 Oct 10. doi: 10.1097/CM9.0000000000003151.
7
Response to letters to the Editor on 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3'.对《阿贝西利联合非甾体芳香化酶抑制剂作为HR+、HER2-晚期乳腺癌的初始治疗：MONARCH 3的最终总生存结果》一文读者来信的回复
Ann Oncol. 2024 Dec;35(12):1202-1204. doi: 10.1016/j.annonc.2024.08.2350. Epub 2024 Oct 15.
8
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.MONARCH 3最终无进展生存期：阿贝西利作为晚期乳腺癌初始治疗的随机研究。
NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
9
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.阿贝西利联合内分泌治疗 HR+/HER2-晚期乳腺癌的亚洲患者：MONARCH 2 和 3 研究。
Cancer Sci. 2021 Jun;112(6):2381-2392. doi: 10.1111/cas.14877. Epub 2021 May 1.
10
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

引用本文的文献

1
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy.接受细胞周期蛋白依赖性激酶4/6抑制剂和内分泌治疗的乳腺癌患者中既往存在和新出现的免疫介导疾病。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf123.